Hypoparathyroidism
Endocrinology·MeSH: Hypoparathyroidism
Prevalence
0.1 / 100K
26 drugs in development·6 companies·9 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| yorvipath | Ascendis Pharma A/S (ASND) |
Phase 2(8)
Phase 1(16)
Preclinical(1)
| Drug | Company |
|---|---|
| pth1r agonist | Septerna, Inc. (SEPN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Hypoparathyroidism?
BioSniper tracks 26 drugs in development for Hypoparathyroidism across 6 companies.
How many clinical trials target Hypoparathyroidism?
There are 9 clinical trials targeting Hypoparathyroidism tracked by BioSniper.
What is the prevalence of Hypoparathyroidism?
The estimated prevalence of Hypoparathyroidism is approximately 0.1 per 100,000 population.
Deep-dive into Hypoparathyroidism
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis